FDG PET/CT对晚期III-IV期BRAF突变黑色素瘤靶向治疗患者无进展生存期的预测价值——从进展模式中能学到什么
这项前瞻性多中心单臂研究纳入70例不可切除III/IV期BRAF突变黑色素瘤患者,在 vemurafenib 联合 cobimetinib 治疗基线、2周和7周及进展时行18F-FDG PET/CT,用RECIST1.1和PERCIST评估反应。7周PERCIST完全代谢反应(CMR)者中位PFS 16.7个月 vs 非CMR 8.5个月,非CMR进展/死亡HR 2.94(95%CI 1.60-5.40;P=0.0005),校正LDH后仍显著。2周CMR者中位PFS 15.7个月 vs 非CMR 8.3个月(P=0.035)。进展时82%(18/22)为已知转移灶进展,治疗中新发FDG高摄取病灶不自动提示复发。
要点
- 7周PERCIST CMR者中位PFS 16.7个月 vs 非CMR 8.5个月,非CMR进展/死亡HR 2.94(95%CI 1.60-5.40;P=0.0005)。
- 2周CMR者中位PFS 15.7个月 vs 非CMR 8.3个月(P=0.035),非CMR进展/死亡HR 1.99(95%CI 1.03-3.84;P=0.040)。
- 7周时4例(6%)新发FDG高摄取病灶但已知转移灶CMR者,PET/CT为假阳性。
核心结论
- 7周PERCIST反应评估可预测PFS,且不受LDH影响。
- 2周CMR者PFS长于非CMR者,但需研究不同PET参数以进一步评估早期18F-FDG PET/CT的附加价值。
- PET/CT所示疾病进展以已知转移灶进展为主,BRAF/MEKi治疗中新发FDG高摄取病灶不自动提示复发。
研究设计与样本
- 前瞻性多中心单臂研究,纳入70例不可切除III/IV期BRAF突变黑色素瘤患者。
- 患者在基线、治疗2周和7周及进展时(如可能)行增强CT和18F-FDG PET/CT。
- 治疗方案为vemurafenib联合cobimetinib。
- 肿瘤反应评估采用RECIST1.1和PERCIST。
- 随访PET/CT与基线视觉比较以评估播散模式。
主要发现
- RECIST1.1评估的各反应组间PFS无显著差异(P=0.26)。
- 2周时PERCIST CMR者中位PFS 15.7个月 vs 非CMR 8.3个月(P=0.035)。
- 2周时非CMR vs CMR的进展/死亡HR 1.99(95%CI 1.03-3.84;P=0.040);校正LDH后HR 1.77(95%CI 0.91-3.43;P=0.0935)。
- 7周时PERCIST CMR者中位PFS 16.7个月 vs 非CMR 8.5个月(P=0.0003);非CMR组进展/死亡HR 2.94(95%CI 1.60-5.40;P=0.0005),校正LDH后HR 2.65(95%CI 1.43-4.91;P=0.0020)。
- 7周时4例(6%)新发FDG高摄取病灶但已知转移灶CMR者,18F-FDG PET/CT为假阳性;进展时18/22(82%)患者为已知转移灶进展伴或不伴新发18F-FDG高摄取病灶。
关键数值与推荐
- PERCIST用于代谢反应评估,RECIST1.1用于常规反应评估。
- 2周CMR定义下中位PFS 15.7个月,非CMR 8.3个月(P=0.035)。
- 7周CMR定义下中位PFS 16.7个月,非CMR 8.5个月(P=0.0003)。
临床怎么用
- 7周PERCIST反应评估可用于预测BRAF/MEKi治疗患者的PFS。
- 2周CMR者PFS长于非CMR者,但早期18F-FDG PET/CT的附加价值需研究不同PET参数进一步评估。
- BRAF/MEKi治疗中新发FDG高摄取病灶不自动视为复发,因7周时该情况均为假阳性。
局限性
- 2周时校正LDH后非CMR vs CMR的HR 1.77(95%CI 0.91-3.43;P=0.0935)未达统计学显著。
- 作者指出需研究不同PET参数以进一步评估早期18F-FDG PET/CT的附加价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aims of this study were to investigate whether (early) PERCIST response monitoring with 18 F-FDG PET/CT is predictive for progression-free survival (PFS) in unresectable stage III or IV melanoma patients treated with BRAF/MEK inhibitor (MEKi) and to define dissemination patterns at progression with a lesion-based evaluation in direct comparison to baseline to improve our understanding of 18 F-FDG PET/CT during BRAF/MEKi. PATIENTS AND METHODS: This prospective multicenter single-arm study included 70 patients with unresectable stage III/IV BRAF -mutated melanoma who underwent contrast-enhanced CT and 18 F-FDG PET/CT at baseline and 2 and 7 weeks during treatment with vemurafenib plus cobimetinib and at progression if possible. Tumor response assessment was done with RECIST1.1 and PERCIST. Follow-up PET/CT scans were visually compared with baseline to assess dissemination patterns. RESULTS: Using RECIST1.1, PFS was not significantly different between the response groups ( P = 0.26). At 2 weeks, PERCIST median PFS was 15.7 months for patients with complete metabolic response (CMR) versus 8.3 months for non-CMR ( P = 0.035). The hazards ratio (HR) for progression/death in non-CMR versus CMR was 1.99 (95% confidence interval [CI], 1.03-3.84; P = 0.040) and 1.77 (95% CI, 0.91-3.43; P = 0.0935) when adjusting for lactate dehydrogenase (LDH). At 7 weeks, median PFS for PERCIST CMR was 16.7 months versus 8.5 months for non-CMR ( P = 0.0003). The HR for progression/death in the non-CMR group was significantly increased (HR, 2.94; 95% CI, 1.60-5.40; P = 0.0005), even when adjusting for LDH (HR, 2.65; 95% CI, 1.43-4.91; P = 0.0020). At week 7, 18 F-FDG PET/CT was false-positive in all 4 (6%) patients with new FDG-avid lesions but CMR of known metastases. When 18 F-FDG PET/CT was performed at progressive disease, 18/22 (82%) patients had progression of known metastases with or without new 18 F-FDG-avid lesions. CONCLUSIONS: This study shows that PERCIST response assessment at week 7 is predictive for PFS, regardless of LDH. At 2 weeks, patients with CMR have longer PFS than patients with non-CMR, but different PET parameters should be investigated to further evaluate the added value of early 18 F-FDG PET/CT. Disease progression on PET/CT is predominated by progression of known metastases, and new 18 F-FDG-avid lesions during BRAF/MEKi are not automatically a sign of recurrent disease.
引用
- van der Hiel B, Aalbersberg EA, van den Eertwegh AJM, et al. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression? Clin Nucl Med. 2023. PMID: 38113329. doi:10.1097/RLU.0000000000004988
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。